Successful Treatment Using Etanercept in a Patient with Enthesitis-Related Arthritis Who Had Late Allergic Reaction to Adalimumab

Creative Commons License

YAĞMUR H., BAYSAL BAKIR D., KABADAYI G., AYDIN T., TORUN R., ATAY Ö., ...Daha Fazla

Pediatric, Allergy, Immunology, and Pulmonology, cilt.38, sa.1, ss.36-39, 2025 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1089/ped.2025.0003
  • Dergi Adı: Pediatric, Allergy, Immunology, and Pulmonology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.36-39
  • Anahtar Kelimeler: etanercept, adalimumab, cross reactions, tumor necrosis factor-alpha inhibitors, drug hypersensitivity
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: Biological agents are considered important therapies and are increasingly used in the treatment of a range of rheumatological and inflammatory diseases. Nevertheless, the prevalent use of these treatments has been associated with increased incidence of drug-induced hypersensitivity reactions (HSR). Case Presentation: A 15-year-old patient with enthesitis-related arthritis developed late HSR after the use of adalimumab. Consequently, etanercept was used as an alternative treatment. Etanercept was administered subcutaneously through a single dose without any reaction upon examination using skin tests (skin prick test, intradermal test, and patch test) against likely cross-reactions given that both adalimumab and etanercept were anti-tumor necrosis factor (TNF) agents. Conclusions: Currently, TNF-α inhibitors find widespread use. Caution is required against HSR reactions, including systemic or local injection site reactions, although they are generally considered safe to use.